| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/26/2004 | US20040038869 Inhibitors of complement activation, their preparation and use |
| 02/26/2004 | US20040038858 Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours |
| 02/26/2004 | US20040038402 Gene therapy; for production of transgenic animal models |
| 02/26/2004 | US20040038363 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/26/2004 | US20040038341 Chimeric human-type vascular endothelial cell growth factor |
| 02/26/2004 | US20040038293 Antibodies to human cd154 |
| 02/26/2004 | US20040038292 Comprises nucleotide sequences which code wound healing proteins for treatment and prevention of scarring, fibrosis, restenosis post angioplasty, psoriasis, benign prostatic hyperplasia, glaucoma and nervous suystem disorders |
| 02/26/2004 | US20040038288 Human protein C Polypeptide |
| 02/26/2004 | US20040038238 Comprises chimeric membrane proteins for diagnosis, treatment and prevention of inflammation, cancer, metabolic, gastrointestinal and autoimmune disorders |
| 02/26/2004 | US20040038235 A g-protein coupled receptor |
| 02/26/2004 | US20040038230 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 02/26/2004 | US20040038223 Comprise polypeptide for diagnosis, prevention and treatment of cardiomyopathy, atherosclerosis, hypertension, cancer, diabetes and nervous system disorders |
| 02/26/2004 | US20040038203 Comprises nucleotide sequences coding yaba monkey tumor viral protein for treatment and prevention of autoimmune diseases |
| 02/26/2004 | US20040037896 Intravenous injection of lignocaine (lidocaine) or a salt, ester or metabolite for use in initiating the natural capacity to regenerate collateral blood vessels; cerebral arterial occlusions; artherosclerosis; angina pectoris |
| 02/26/2004 | US20040037888 Administering intrarectally or to anorectal region aqueous gel composition containing drug effective in such treatment and carrier comprising water soluble cellulose derivative gelling agent, propylene glycol, water |
| 02/26/2004 | US20040037827 Administering antibody to integrin |
| 02/26/2004 | US20040037806 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 02/26/2004 | US20040037022 Aminoalcohol derivatives |
| 02/26/2004 | CA2496419A1 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| 02/26/2004 | CA2495452A1 Use of reboxetine for the treatment of hot flashes |
| 02/26/2004 | CA2495409A1 Diaryl compounds as monoamine reuptake inhibitors |
| 02/26/2004 | CA2495184A1 Thrombopoietin receptor activators and process for their production |
| 02/26/2004 | CA2494847A1 Enos mutants useful for gene therapy |
| 02/26/2004 | CA2494845A1 Gene therapy for critical limb ischemia with wild type or mutant enos |
| 02/26/2004 | CA2493245A1 Novel quinuclidine derivatives and their use |
| 02/25/2004 | EP1391516A1 Von willebrand factor (vwf)-cleaving enzyme |
| 02/25/2004 | EP1391514A1 Pharmaceutical composition for treatment of angiogenesis-dependent conditions |
| 02/25/2004 | EP1391512A1 Polypeptide serving as angiogenic marker and dna thereof |
| 02/25/2004 | EP1391460A1 Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors |
| 02/25/2004 | EP1391457A1 Substituted 2-Phenylbenzimidazoles and their use as PARP inhibitors |
| 02/25/2004 | EP1391456A1 2-iminoimidazole derivative (2) |
| 02/25/2004 | EP1391454A1 Substituted benzamide compounds with antihypertensive activity |
| 02/25/2004 | EP1391453A1 Pyroglutamic acid salt of amlodipine |
| 02/25/2004 | EP1391451A1 2-iminopyrrolidine derivates |
| 02/25/2004 | EP1391426A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate |
| 02/25/2004 | EP1391199A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient |
| 02/25/2004 | EP1390740A1 Methods and formulations for increasing the affinity of a 1? adenosine receptor ligands for the a 1? adenosine receptor |
| 02/25/2004 | EP1390543A2 New polynucleotides and polypeptides of the ifnalpha-17 gene |
| 02/25/2004 | EP1390508A2 A retinoic acid metabolizing cytochrome p450 |
| 02/25/2004 | EP1390496A2 Glutamate receptor modulatory proteins and nucleic acids encoding them |
| 02/25/2004 | EP1390473A2 Methods and reagents for cell transplantation |
| 02/25/2004 | EP1390470A2 Production of alpha-lipoic acid |
| 02/25/2004 | EP1390403A2 Peptides derived from neural thread proteins and their medical use |
| 02/25/2004 | EP1390391A1 Transporters and ion channels |
| 02/25/2004 | EP1390385A2 Nucleic acid based modulation of female reproductive diseases and conditions |
| 02/25/2004 | EP1390378A1 Pharmaceutically active uridine esters |
| 02/25/2004 | EP1390366A1 The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene |
| 02/25/2004 | EP1390365A1 Novel sulfonate substituted pyrazol pyridine dervivatives |
| 02/25/2004 | EP1390363A2 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 02/25/2004 | EP1390362A1 Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists |
| 02/25/2004 | EP1390361A2 Melanocortin receptor ligands |
| 02/25/2004 | EP1390357A2 Anti-thrombotic compounds, production and use thereof as medicaments |
| 02/25/2004 | EP1390353A1 Triazole-derived kinase inhibitors and uses thereof |
| 02/25/2004 | EP1390349A1 Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands |
| 02/25/2004 | EP1390348A1 5-cyano-1h-indole derivatives as antagonists of the interleukine-8 receptors |
| 02/25/2004 | EP1390080A1 Azo compounds for type i phototherapy |
| 02/25/2004 | EP1390077A2 Treatment and diagnosis of macrophage mediated disease |
| 02/25/2004 | EP1390070A1 Use of il-18 inhibitors for treating or preventing cns injuries |
| 02/25/2004 | EP1390061A2 Chronic treatment regimen using glucagon-like insulinotropic peptides |
| 02/25/2004 | EP1390057A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use |
| 02/25/2004 | EP1390055A2 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| 02/25/2004 | EP1390054A2 Mu-conopeptides |
| 02/25/2004 | EP1390045A1 The use of a compound with a negatively charged domain of radicals for the treatment of restenosis |
| 02/25/2004 | EP1390034A1 N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists |
| 02/25/2004 | EP1390025A1 Coenzyme q and eicosapentaenoic acid (epa) |
| 02/25/2004 | EP1390024A1 Isostearic acid salts as permeation enhancers |
| 02/25/2004 | EP1390018A1 A pharmaceutical tablet having a high api content |
| 02/25/2004 | EP1390014A1 Composition and methods for treatment of hyperplasia |
| 02/25/2004 | EP1390013A2 Therapeutic treatments using the direct application of antimicrobial metal compositions |
| 02/25/2004 | EP1390011A2 Control of compactability through crystallization |
| 02/25/2004 | EP1389970A2 Compositions and methods of double-targeting virus infections and cancer cells |
| 02/25/2004 | EP1263756B1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 02/25/2004 | EP1236735B1 Benzamidine derivatives |
| 02/25/2004 | EP1222171B1 Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
| 02/25/2004 | EP1210326B1 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 02/25/2004 | EP1178986B1 Furanone derivatives as inhibitors of cathepsin s |
| 02/25/2004 | EP1165064B1 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 02/25/2004 | EP1140931B1 5ht1 antagonists for antidepressant therapy |
| 02/25/2004 | EP1117392B1 Method for preventing or delaying catheter-based revascularization |
| 02/25/2004 | EP1087934B1 Aminocyclohexyl ether compounds and uses thereof |
| 02/25/2004 | EP1042296B1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 02/25/2004 | EP1037612B1 Pharmaceutical compositions containing micronized bicyclic drugs |
| 02/25/2004 | EP0981526B1 Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them |
| 02/25/2004 | EP0946181B1 Use of 2-(2-morpholinophenyl) guanidine derivatives for the treatment of diabetes complications |
| 02/25/2004 | EP0883405B1 Amidino protease inhibitors |
| 02/25/2004 | EP0873301B1 Indane compounds with smooth muscle relaxing and/or mast cell stabilising and/or anti-inflammatory activity |
| 02/25/2004 | EP0758897B1 Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| 02/25/2004 | EP0751957B1 Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases |
| 02/25/2004 | EP0749478B1 Yeast strains and modified albumins |
| 02/25/2004 | CN1478087A Indolylmaleimide derivatives as protein kinase C inibitors |
| 02/25/2004 | CN1478085A ABCA-1 elevating compounds against coronary artery disease or atherosclerosis |
| 02/25/2004 | CN1478084A Compounds useful in treatment of inflammatory diseases |
| 02/25/2004 | CN1478081A Substituted 2-znilino-benzimidazoles and use thereof as NHE-inhibitors |
| 02/25/2004 | CN1478080A Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 02/25/2004 | CN1478078A Nitrogenous aromatic ring compounds |
| 02/25/2004 | CN1478077A Benzamide compounds as APOB secretion inhibitors |
| 02/25/2004 | CN1478076A MCH antagonists and their use in treatment of obesity |
| 02/25/2004 | CN1477977A Compositions of N-(methy/ethy/aminocarbony/)-4-(3-methy/pheny/amino)-3-pyridy/sulfonamide and cyclic oligosaccharides |
| 02/25/2004 | CN1477976A Combination of GABA agonists and aldose reductase inhibitors |
| 02/25/2004 | CN1477975A Combination of GABA agonists and sorbitol dehydrogenase inhibitors |